Cross Resistance | malecare.org

Does Prior Response to Zytiga Affect Subsequent Activity of Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC)?

Given all the newly approved drugs available to us to treat advanced prostate cancer there now are many questions about the optimal sequencing of these drugs and whether earlier use of one causes cross-resistance to another. Recently, it was reported that chemotherapy with docetaxel is inactive in men with metastatic castrate resistant prostate cancer (mCRPC) [...]

By Malecare|2017-10-19T10:48:19-04:00May 21st, 2014|abiraterone acetate, Advanced Prostate Cancer, Chemo Therapy, Chemo Therapy Failure, Cross Resistance, Drugs & Treatments, Research, Uncategorized, Understanding APC, Zytiga|0 Comments

Impact of Prior Abiraterone Acetate (Zytiga) on Subsequent Activity of Docetaxel (Chemotherapy) in Men with Metastatic Castration-Resistant Prostate Cancer

The explosion of new therapies for men with metastatic castration resistant prostate cancer (mCRPC) raises serious questions about the optimal sequencing of these new treatments as well as whether cross-resistance occurs between these drugs. It was recently reported that chemotherapy with docetaxel (D) is not effective in in men who did not have a ? [...]

By Malecare|2017-10-19T10:48:29-04:00April 1st, 2014|abiraterone acetate, Advanced Prostate Cancer, Chemo Therapy, Chemo Therapy Failure, Cross Resistance, Drugs & Treatments, Uncategorized, Understanding APC, Zytiga|0 Comments

More Issues Raised About Cross-Resistance Between Abiraterone and Enzalutamide

Some of my posts over the last week or two have discussed the issue of the development of cross-resistance of two of our newest treatments for advanced prostate cancer. These drugs are abiraterone (Zytiga) and enzalutamide (Xtandi). Currently, both of them are approved for use after a man has failed chemotherapy with docetaxel. In addition, [...]

By Malecare|2017-10-19T10:48:30-04:00March 13th, 2014|abiraterone acetate, Advanced Prostate Cancer, Cross Resistance, enzalutamide, Uncategorized, Understanding APC, Xtandi, Zytiga|0 Comments

There is Some Cross Resistance Developed Between Both the First Use of Zytiga and the First Use of Xtandi

On March 4, 2014 I wrote a post “Castrate Resistant Prostate Cancer- What to Do Next” (www.advancedprostatecancer.net/?p=4425). The basic theme of the post was about how difficult it is to know how to sequence the new drugs we have to treat advanced prostate cancer (metastatic castrate resistant prostate cancer aka mCRPC). In the post I [...]

By Malecare|2017-10-19T10:48:32-04:00March 7th, 2014|abiraterone acetate, Advanced Prostate Cancer, Combination Therapy, Cross Resistance, Drugs & Treatments, enzalutamide, Uncategorized, Understanding APC, Xtandi, Zytiga|0 Comments